Abstract
Introduction: The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil
as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not
candidates for combination with cytotoxic chemotherapies.
Discussion: TASCO1 Trial was considered (153 patients). Differences in costs between the 2 arms
(trifluridine/tipiracil plus bevacizumab vs. capecitabine plus bevacizumab) was 9113
€ (10 264 USD), with a cost savings of 1982 € (2232 USD) per month of overall survival
(OS)-gain.
Conclusion: Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line
for mCRC patients who were not candidates for combination with cytotoxic chemotherapies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Randomized trial of TAS-102 for refractory metastatic colorectal cancer.N Engl J Med. 2015; 372: 1909-1919
- Regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer? a perspective on the basis of pharmacological costs.Clin Colorectal Cancer. 2018; 17: e381-e383
- Economic sustainability of trifluridine/tipiracil for the treatment of refractory metastatic colorectal cancer in real life.Clin Colorectal Cancer. 2020; 19: 181-182
- Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.Ann Oncol. 2020; 31: 1160-1168
- Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): results of the final analysis on the overall survival.J Clin Oncol. 2021; 39: 14
- The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab.Anticancer Res. 2019; 39: 3971-3973
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).Ann Oncol. 2015; 26: 1547-1573
- Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018.Eur J Cancer. 2018; 104: 233-235
- The cost of cancer in Europe 2018.Eur J Cancer. 2020; 129: 41-49
- The effectiveness of cost-effectiveness analysis in containing costs.J Gen Intern Med. 1998; 13: 664
- Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors.Anticancer Res. 2019; 39: 3961-3965
- Immunotherapy in first-line for advanced non-small cell lung cancer:a cost-effective choice?.Recenti Prog Med. 2019; 110: 138-143
- Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.Oral Oncol. 2019; 97: 143-145
- Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs.Clin Lung Cancer. 2017; 18: e363-e365
- Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma.Clin Genitourin Cancer. 2018; 16: e557-e562
Article info
Publication history
Published online: December 04, 2021
Accepted:
November 30,
2021
Received in revised form:
November 24,
2021
Received:
June 27,
2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
